Abstract
Debrisoquine is an antihypertensive drug that displays polymorphic metabolism and has been used to determine hydroxylator status in human subjects. A high-performance liquid chromatographic method for the simultaneous urine analysis of debrisoquine (D) and its primary metabolite, 4-hydroxydebrisoquine (4-OHD), is described. A cyanopropyl (CN) extraction column and CN analytical column were used with a mobile phase consisting of 20% acetonitrile/20 mM sodium dihydrogen orthophosphate (pH = 7.1) at a flow rate of 1.5 ml/min. The peaks of interest, as well as the internal standard, were eluted from the column in less than 14 min. The method described was validated for within-day and between-day accuracy and precision for both D and 4-OHD. Coefficients of variation at all concentrations tested were <4.1% for D and <9.3% for 4-OHD. The assay was used to evaluate D/4-OHD ratios, thereby determining hydroxylation status in 65 healthy male volunteers.
Original language | English (US) |
---|---|
Pages (from-to) | 478-480 |
Number of pages | 3 |
Journal | Therapeutic drug monitoring |
Volume | 12 |
Issue number | 5 |
DOIs | |
State | Published - Sep 1990 |
Keywords
- 4-Hydroxydebrisoquine
- Debrisoquine
- High-performance liquid chromatography
- Metabolism
- Polymorphic